Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the <scp>HypoBar</scp> I Randomised Clinical Trial
HypoBar I is the first randomised, placebo-controlled study of the treatment of PBH with acarbose or canagliflozin. Reduction in time below range was not achieved by either treatment; nevertheless, improvements in hypothesis-generating secondary findings merit further investigation and validation. EudraCT number 2022-000157-87.
Authors
- Christoffer Martinussen (ORCID: https://orcid.org/0000-0002-7210-0807)
- Carsten Dirksen (ORCID: https://orcid.org/0000-0002-2173-6469)
- Nils B. Jørgensen (ORCID: https://orcid.org/0000-0002-5764-6377)
- Kirstine N. Bojsen‐Møller (ORCID: https://orcid.org/0000-0003-1962-5302)
- Simon Veedfald (ORCID: https://orcid.org/0000-0002-0797-3417)
- Carolina B. Lobato
- Sten Madsbad
- Bolette Hartmann
- Clara Tornøe Winding
- Jens J. Holst
Institutions
- University of Copenhagen (DK)
- Novo Nordisk Foundation (DK)
- Hvidovre Hospital (DK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1111/dom.70611
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00